Analysis of Immune Checkpoint Control Protein Co-expression in Breast and Ovarian Cancer Using Novel Rabbit Monoclonal Antibodies and Multiplex IHC

With an increasing number of biomarkers and, often, limited availability of biopsy material, there is a growing need for multiplexed assays for both research and clinical purposes. IHC based solutions are particularly attractive in the field of immuno-oncology, as maintaining spatial context within the tumor microenvironment provides meaningful and potentially actionable information. Immuno-assays with high specificity and sensitivity are a powerful tool, however, there are challenges associated with antibody based multiplexing when you wish to concurrently analyze beyond 2-3 markers.

A multiplex IHC solution that bypasses antibody species/isotype concerns, while providing signal amplification, was used to examine the co-expression of immune checkpoint control proteins, such as PD-L1, B7-H3, B7-H4, and VISTA, in breast and ovarian cancer.

Speaker

Matthew R. Silver, Ph.D, Principal Scientist, Translational Assays, Cell Signaling Technology

Matthew Silver leads the Translational Assays Group at Cell Signaling Technology, Inc. where he focuses on the development of both translational research reagents and multiplex assays. Matthew received his PhD in Biochemistry from the University of New Hampshire where he studied the neuroendocrine regulation of reproduction. His subsequent postdoctoral studies were performed at Wyeth Research within the Department of Inflammation.

Message Presenter